ClinicalTrials.gg
CompletedNCT03596164Updated Mar 15, 2023Results posted

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

A Phase 3 interventional study of Teduglutide and Syringe in Short Bowel Syndrome, sponsored by Takeda. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
13th of 20
11 · median 20
Started
2018
with 3 others
Phase 3
16 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
3 of 20
Takeda

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 13th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 16th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the long-term safety and efficacy of teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent SBS (short bowel syndrome) who completed SHP633-306 or who were in the extension phase of the TED-C14-004 (NCT02340819) study.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet all of the following criteria will be enrolled in this study:

  1. Ability to voluntarily provide written, signed, and to participate in the study.
  2. Completion of the SHP633-306 study or participation in TED-C14-004 (NCT02340819) Stage 3 or Stage 4.
  3. Females of must agree to comply with the requirements of the protocol.
  4. An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion criteria

Exclusion Criteria:

There are no exclusion criteria for this study.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Teduglutide 0.05 mg

    Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.

    Drug: Teduglutide · Device: Syringe · Device: Needle · Device: Vial Adapter for Device

Interventions

  • Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.

  • DeviceSyringe

    Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.

  • DeviceNeedle

    Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.

  • DeviceVial Adapter for Device

    Vial adapter for device is approved for use in Japan by PMDA.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume

    The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  2. Change From Baseline in Weekly PS Volume

    The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  3. Percent Change From Baseline in Weekly PS Volume

    The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  4. Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)

    Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)

  5. Change From Baseline in Days Per Week of PS

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  6. Change From Baseline in Plasma Citrulline Levels

    Plasma citrulline was measured as an assessment of enterocyte mass. Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)

  8. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  9. Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  10. Number of Participants With Clinically Significant Change From Baseline in Laboratory Values

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  11. Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS

    Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)

  12. Change From Baseline in 48-Hour Urine Output

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  13. Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  14. Number of Participants With Clinically Significant Change From Baseline in BMI

    Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

    Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)

  15. Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results

    Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)

07

Results

Posted Mar 15, 2023

Participant flow

Participants took part in the study at 5 investigative sites in Japan from 09 July 2018 to 13 January 2022.

Participant flow — Overall Study
MilestoneSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Started47
Completed36
Not completed11
Withdrew: Adverse event01
Withdrew: Death10

Outcome measures

PrimaryNumber of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume

The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume35
PrimaryChange From Baseline in Weekly PS Volume

The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Mean · liter per week (L/Week)
Change From Baseline in Weekly PS Volume
liter per week (L/Week)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Change From Baseline in Weekly PS Volume-7.45 ± 7.908-8.67 ± 7.450
PrimaryPercent Change From Baseline in Weekly PS Volume

The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Mean · percent change
Percent Change From Baseline in Weekly PS Volume
percent changeSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Percent Change From Baseline in Weekly PS Volume-49.55 ± 41.411-52.52 ± 39.828
PrimaryNumber of Participants Who Were Completely Weaned Off PS at End of Study (EOS)
Time frame:
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)12
PrimaryChange From Baseline in Days Per Week of PS

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Mean · days per week
Change From Baseline in Days Per Week of PS
days per weekSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Change From Baseline in Days Per Week of PS-2.3 ± 3.30-2.0 ± 3.42
PrimaryChange From Baseline in Plasma Citrulline Levels

Plasma citrulline was measured as an assessment of enterocyte mass. Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Mean · micromoles per liter
Change From Baseline in Plasma Citrulline Levels
micromoles per literSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kg
Change From Baseline in Plasma Citrulline Levels12.96 ± 5.56819.15 ± 18.851
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame:
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
TEAE4711
TESAE347
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Values

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values000
PrimaryNumber of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS
Time frame:
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS347
PrimaryChange From Baseline in 48-Hour Urine Output

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Mean · Milliliter per day (mL/day)
Change From Baseline in 48-Hour Urine Output
Milliliter per day (mL/day)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Change From Baseline in 48-Hour Urine Output428.8 ± 286.57308.6 ± 589.36352.3 ± 486.54
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Body Weight Measurements

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements000
PrimaryNumber of Participants With Clinically Significant Change From Baseline in BMI

Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.

Time frame:
Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in BMI
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Change From Baseline in BMI000
PrimaryNumber of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results
Time frame:
From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results
ParticipantsSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results000

Adverse events

Collected over TEAEs were defined as AEs that started on or after the first dose of study drug (in current study) up to approximately 42 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHP633-306: Teduglutide 0.05 mg/kg1/4 (25%)3/4 (75%)4/4 (100%)
TED-C14-004: Teduglutide 0.05 mg/kg0/7 (0%)4/7 (57.1%)7/7 (100%)
Total Participants1/11 (9.1%)7/11 (63.6%)11/11 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
Device related infectionInfections and infestations0/44/74/11
CholecystitisHepatobiliary disorders1/40/71/11
DehydrationMetabolism and nutrition disorders1/40/71/11
Device breakageProduct Issues1/40/71/11
Device occlusionProduct Issues1/40/71/11
EpilepsyNervous system disorders1/40/71/11
Hepatic failureHepatobiliary disorders1/40/71/11
Metabolic acidosisMetabolism and nutrition disorders1/40/71/11
PyrexiaGeneral disorders1/40/71/11
SepsisInfections and infestations1/40/71/11
Most frequent other events
Showing 10 of 61
Most frequent other events
EventSHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal Participants
HypokalaemiaMetabolism and nutrition disorders2/41/73/11
NasopharyngitisInfections and infestations2/43/75/11
InfluenzaInfections and infestations1/43/74/11
DiarrhoeaGastrointestinal disorders0/42/72/11
EczemaSkin and subcutaneous tissue disorders0/42/72/11
EnterocolitisGastrointestinal disorders0/42/72/11
Abdominal distensionGastrointestinal disorders1/40/71/11
Anal abscessInfections and infestations1/41/72/11
Back painMusculoskeletal and connective tissue disorders1/41/72/11
CellulitisInfections and infestations1/40/71/11

Baseline characteristics

The safety population included all enrolled participants in the study. Data reported in baseline measures was collected at baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]).

Age, Continuous
Age, Continuous(years)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Mean40.8 ± 12.2842.4 ± 7.2141.8 ± 8.78
Sex: Female, Male
Sex: Female, Male(Participants)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Female224
Male257
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Hispanic or Latino000
Not Hispanic or Latino4711
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
American Indian or Alaska Native000
Asian4711
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Japan4711
Height
Height(centimeter (cm))SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Mean161.10 ± 6.168167.77 ± 6.735165.35 ± 7.068
Weight
Weight(kilogram (kg))SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Mean49.29 ± 10.01056.01 ± 10.95853.57 ± 10.660
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))SHP633-306: Teduglutide 0.05 mg/kgTED-C14-004: Teduglutide 0.05 mg/kgTotal
Mean18.96 ± 3.44119.80 ± 3.15319.49 ± 3.114
08

Study locations

5 sites
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima-ken 734-8551, Japan
  • Hyogo College of Medicine Hospital
    Hyogo, 663-8501, Japan
  • Tohoku University Hospital
    Miyagi-Ken, 980-8574, Japan
  • Osaka University Hospital
    Osaka, 565-0871, Japan
  • Yokohama Municipal Citizen's Hospital
    Yokohama, 240-8555, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2022, 42 months.

Results were first posted in Mar 2023, 1 year 2 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 42 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2018
First posted
Jul 23, 2018
StartActual
Jul 9, 2018
Primary completionActual
Jan 13, 2022
CompletionActual
Jan 13, 2022
Results first posted
Mar 15, 2023
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03596164
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 23, 2018
Start date
Jul 9, 2018
Primary completion
Jan 13, 2022
Completion
Jan 13, 2022
Results posted
Mar 15, 2023
Last update
Mar 15, 2023

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion